Gregory Riedlinger – Research output — Rutgers, The State University of New Jersey

View Scopus Profile

Emailgr338rutgersedu

h-index

Research activity per year

38 Article
2 Conference contribution
2 Letter
2 Review article
More

1 results

Filter

2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers (Nature, (2022), 608, 7923, (609-617), 10.1038/s41586-022-05066-5)
Zingg, D., Bhin, J., Yemelyanenko, J., Kas, S. M., Rolfs, F., Lutz, C., Lee, J. K., Klarenbeek, S., Silverman, I. M., Annunziato, S., Chan, C. S., Piersma, S. R., Eijkman, T., Badoux, M., Gogola, E., Siteur, B., Sprengers, J., de Klein, B., de Goeij-de Haas, R. R. & Riedlinger, G. M. & 28 others, Ke, H., Madison, R., Drenth, A. P., van der Burg, E., Schut, E., Henneman, L., van Miltenburg, M. H., Proost, N., Zhen, H., Wientjens, E., de Bruijn, R., de Ruiter, J. R., Boon, U., de Korte-Grimmerink, R., van Gerwen, B., Féliz, L., Abou-Alfa, G. K., Ross, J. S., van de Ven, M., Rottenberg, S., Cuppen, E., Chessex, A. V., Ali, S. M., Burn, T. C., Jimenez, C. R., Ganesan, S., Wessels, L. F. A. & Jonkers, J., Sep 29 2022, In: Nature. 609, 7929, p. E13
Research output: Contribution to journal › Comment/debate › peer-review

Open Access
2 Scopus citations